FDA
-
-
-
-
-
-
-
Sight Sciences (SGHT) Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI Across Mild, Moderate, and Advanced Glaucoma
-
-
-
-
-
-
-
Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medicat
-
-
-
-
-
-
-
Sight Sciences' Glaucoma and Dry Eye Technologies to be Featured in Multiple Clinical Presentations at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
-
-
-
-
-
-
-
Improvements in Signs and Symptoms of Dry Eye Disease From a Single TearCare® Treatment Sustained Through 12 Months
-
-
-
-
-
-
-
Sight Sciences OMNI® Surgical System to Be Featured in Multiple Presentations at the 2022 European Society of Cataract and Refractive Surgery Annual Meeting
-
-
-
-
-
-
-
Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI® Surgical System in Patients with Open Angle Glaucoma
-
-
-
-
-
-
-
Sight Sciences Launches “Don’t Wait for Too Late” Awareness Campaign for Glaucoma
-
328,282 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

